15/01/2024 – AB Science today announced that the European Patent Office has issued a Notice of Allowance for a patent relating to methods of treating severe systemic mastocytosis with its lead compound masitinib, based on findings from study AB06006 Download PDF Post navigationPreviousPrevious post:AB Science webcast – Masitinib in Sickle Cell DiseaseNextNext post:AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines AgencyRelated PostsPositive results of the Phase 2 study evaluating masitinib in Covid-19July 8, 2024AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALSJune 28, 2024June 26, 2024 CGM – Q&A documentJune 26, 2024Summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALSMay 31, 2024AB Science webcast of May 30, 2024May 30, 2024AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALSMay 29, 2024
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALSJune 28, 2024
Summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALSMay 31, 2024
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALSMay 29, 2024